Publicado em 31 jan 2023
PANORAMIC: important insights into molnupiravir use in COVID-19
The Lancet – Oral antivirals have been an important addition to efforts to minimise adverse COVID-19 outcomes in individuals at high risk. Although no head-to-head comparisons of the widely available treatments molnupiravir and nirmatrelvir–ritonavir have been published, early trial findings (done largely in unvaccinated populations during pre-omicron SARS-CoV-2 waves) suggested less benefit from molnupiravir.
Leia matéria na íntegra em https://www.thelancet.com/
